Novocure Denmark ApS: Financial statements 2023
CVR: 43071076
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Novocure Denmark ApS (CVR 43071076) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 8,274,042 and a net result of DKK 433,261 compared with DKK 106,272 the year before. That is an increase of 337.9% compared with the year before. Equity in the 2023 report amounted to DKK 579,533. The solvency ratio was 9.4%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 8,274,042
- Profit/Loss
- DKK 433,261
- Equity
- DKK 579,533
- Total Assets
- DKK 6,182,962
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 8.3 mio. | 433 t. | 580 t. | 4 |
| 2022 | - | 1.9 mio. | 106 t. | 146 t. | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Novocure Denmark ApS has published its interim report for the period February 15, 2022 – December 31, 2022.
About Novocure Denmark ApS
Novocure Denmark ApS is a Danish company of the type Anpartsselskab based in Viby J, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Marco Adriano Carrino. The company is owned by Novocure GmbH. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 1,313,877 and a net result of DKK 52,751 compared with DKK 833,715 the year before. Equity in the 2025 report amounted to DKK 1,465,999.